A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients.

ABSTRACT:

Aims

There are no specific criteria for a step-down or withdrawal dose of omalizumab (OMA). Our purpose was to evaluate the viability of a protocol for OMAlizumab DOse REduction (the OMADORE study) in severe allergic asthma (SAA).

Methods

The study population included 35 SAA patients treated during a minimum period of 1 year with oral corticosteroids (OC) equivalent to a mean daily dose of 4 mg of methyl-prednisolone. To qualify for the protocol, the patients had to have received treatment with OMA for at least one and a half years, OC dose had to have reached the lowest tolerated dose and spirometry had to be greater than or equal to that at entry. The interventions were (a) OMA dose was reduced by half; (b) if patients were clinically stable after 6 months, the dose was ha

SUBMITTER: Domingo C 

PROVIDER: S-EPMC5777444 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature